Market Cap 1.17B
Revenue (ttm) 333.62M
Net Income (ttm) -39.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.73%
Debt to Equity Ratio 0.87
Volume 4,524,900
Avg Vol 3,904,142
Day's Range N/A - N/A
Shares Out 238.36M
Stochastic %K 25%
Beta 0.87
Analysts Strong Sell
Price Target $10.86

Latest News on ARDX

Tenapanor Approved in China for Hyperphosphatemia

Feb 26, 2025, 7:00 AM EST - 5 weeks ago

Tenapanor Approved in China for Hyperphosphatemia


Ardelyx to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:15 PM EST - 5 weeks ago

Ardelyx to Participate in Upcoming Investor Conferences


3 Biotech/Healthcare Names Under $10 I Am Buying Now

Feb 21, 2025, 4:21 PM EST - 5 weeks ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

GERN MRNA PSNL TEM


Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:32 PM EST - 5 weeks ago

Ardelyx, Inc. (ARDX) Q4 2024 Earnings Call Transcript


Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Nov 14, 2024, 9:34 AM EST - 4 months ago

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability


Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 11:20 PM EDT - 5 months ago

Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript